Group A (n = 9) | Start | 3 months | 6 months | 9 months | 12 months |
Levodopa (mg) | 723 ± 15 | 722 ± 11 | 722 ± 6 | 723 ± 6 | 730 ± 8 |
Dopaminergic agonists | |||||
Pramipexol, no. patients (mg) | 9 (2.6 ± 0.2) | 3 (2.1 ± 0.2) | - | - | - |
Pen-delivered apomorphine |
|
|
|
|
|
mg/day | 66 ± 3 | 32 ± 4 | 18 ± 2 | 5 ± 2 | - |
no. boluses | 8 | 2 | 2 | 1 |
|
Apomorphine in perfusion |
|
|
|
|
|
ml/h | 0.4 ± 0.2 | 0.8 ± 0.2 | 0.8 ± 0.2 | 1 ± 0.1 | 1.2 ± 0.2 |
12 hours/day | 12 | 11.8 ± 0.2 | 11.8 ± 0.2 | 11.6 ± 0.4 | 11.4 ± 0.6 |
no. boluses (bolus volume) | 2 (0.4 ml) | 3 (0.3 ml) | 3 (0.3 ml) | 2 (0.3 ml) | 2 (0.3 ml) |
Group B (n = 6) | Start | 3 months | 6 months | 9 months | 12 months |
Levodopa (mg) | 920 ± 12 | 923 ± 10 | 933 ± 5 | 910 ± 20 | 915 ± 16 |
Dopaminergic agonists: | |||||
Rotigotine no. patients (mg) | 6 (12 ± 2) | 3 (6 ± 2) | 1 (4 ± 2) | 1 (4 ± 2) | 1 (4 ± 2) |
Pramipexole no. patients (mg) | 3 (2.1 ± 0.0) | - | - | - | - |
Pen-delivered apomorphine |
|
|
|
|
|
mg/day | 64 ± 4 | 42 ± 6 | 12 ± 2 | 5 | 4 |
no. boluses | 5 | 3 | 2 | 1 | 1 |
Apomorphine in perfusion |
|
|
|
|
|
ml/h | 0.4 ± 0.2 | 0.8 ± 0.2 | 0.9 ± 0.2 | 0.9 ± 0.1 | 0.9 ± 0.1 |
12 hours/day | 12 | 11.7± 0.2 | 11.5 ± 0.1 | 11.1 ± 0.2 | 11.1 ± 0.2 |
no. boluses (bolus volume) | 3 (0.4ml) | 2 (0.3ml) | 2 (0.3ml) | 2 (0.3ml) | 2 (0.3ml) |